SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Melichar, J. K.
Right arrow Articles by Malizia, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Melichar, J. K.
Right arrow Articles by Malizia, A. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers

Jan K. Melichar

Psychopharmacology Unit, University of Bristol, Bristol BS8 1TD UK jan_melichar{at}bristol.ac.uk

Abel Haida

Chris Rhodes

MRC Cyclotron Unit, Hammersmith Hospital, London

Alan H. Reynolds

Wyeth Laboratories, Taplow, Maidenhead, Berkshire, UK

David J. Nutt

Andrea L. Malizia

Psychopharmacology Unit, University of Bristol, Bristol

Venlafaxine, a serotonin and noradrenaline reuptake inhibitor, is an effective antidepressant at doses of 75 mg p.o. daily and above. Preclinical and healthy volunteer studies have demonstrated that venlafaxine is more potent at the serotonin than at the noradrenaline reuptake site, with noradrenergic blocking effects being observed at doses >75 mg p.o. in man. We used the Multiple Organs Coincidences Counter and [11C] meta hydroxy ephedrine (MHED) to test whether significant occupation of cardiac sympathetic neurones was achieved in man in vivo after the acute administration of venlafaxine 75 mg p.o. in nine healthy volunteers. MHED is a tracer which binds at the noradrenaline reuptake site. This study demonstrates that the [11C]MHED signal is significantly reduced after the administration of venlafaxine 75 mg p.o. thus showing that noradrenaline reuptake blockade is observable at this dose. This effect is predominantly seen in volunteers who received > 1 mg/kg venlafaxine.

Key Words: depression • metahydroxyephedrine • noradrenaline reuptake site • PET • sympathetic • venlafaxine

Journal of Psychopharmacology, Vol. 15, No. 1, 9-12 (2001)
DOI: 10.1177/026988110101500102


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
J Deakin and C O'Loughlin
STAR*D: a summary and UK perspective
J Psychopharmacol, August 1, 2009; 23(6): 605 - 612.
[PDF]


Home page
NeurologyHome page
D. S. Goldstein, R. Imrich, E. Peckham, C. Holmes, G. Lopez, C. Crews, J. Hardy, A. Singleton, and M. Hallett
Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation
Neurology, October 16, 2007; 69(16): 1580 - 1584.
[Abstract] [Full Text] [PDF]



Advertisement